자가주사기 시장 규모, 점유율, 동향 분석 : 제품별, 사용성별, 용도별, 지역별, 부문별 예측(2025-2030년)

Self-injection Devices Market Size, Share & Trends Analysis By Product (Auto Injectors, Pen Injectors), By Usability (Disposable, Reusable), By Application (Cancer, Autoimmune Disorders, Hormonal Disorders), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,287,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,679,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,465,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

자가주사기 시장 성장 및 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 자가주사기 시장 규모는 2025년부터 2030년까지 10.31%의 CAGR을 기록하며 2030년까지 405억 달러에 달할 것으로 예상됩니다.

환자 수 증가, 만성질환 유병률 증가, 첨단 약물전달 시스템의 높은 채택률 등은 자가 주사 장치에 대한 수요가 급증할 것으로 추정되는 요인입니다.

의료 종사자와 기업이 자가주사기와 같은 자가 주사 장치를 도입하는 주요 요인은 바늘에 찔리는 부상을 방지하는 것입니다. 미국, 유럽 및 기타 시장에서는 의료 종사자의 바늘에 찔리는 부상을 방지하기 위해 안전 장치 사용을 의무화하고 있습니다. 일부 자동 주사기는 의료진에게 바늘에 찔리지 않는 추가 혜택을 제공합니다. 미국에서는 연간 약 69,000건의 부상을 예방할 수 있을 것으로 예상됩니다. 많은 자동 주사기에는 부상 위험을 제거하거나 줄이는 통합 및 수동 안전 기능이 내장되어 있습니다.

새로운 약물전달 시스템(NDDDS) 분야의 혁신은 자가 투여 약물에 대한 수요 증가로 이어지고 있습니다. 미리 채워진 주사기, 펜형 주사기, 자동 주사기, 무침 주사기 등 새로운 주사제 전달 장비의 발명은 환자의 약물 자가 투여를 더욱 쉽고 편리하게 만들었습니다. 대부분의 생물학적 제제는 주사를 통해 투여되는데, 이는 바늘에 찔리는 손상의 위험이 있습니다. 이 문제를 최소화하기 위해 제약회사는 자가 주사 바늘이 필요 없는 주사기 및 환자 친화적인 약물과 기기의 조합 제품을 개발하고 있습니다.

COVID-19 팬데믹은 투약 환경에 대한 기대와 인식을 변화시켜 자가 투약에 대한 선호도를 높이는 데 일조했습니다. COVID-19 백신은 주사기에 대한 수요를 증가시킬 것이며, 팬데믹은 자가 사용 및 커넥티드 디바이스의 이점을 보여주었으며, 일부 제조업체들은 약물전달 설계에서 환자 경험을 중요한 요소로 삼는 경향이 있습니다. 팬데믹 이후, 향후 기기 혁신이 가속화될 것으로 보이며, 제약사들은 앱, 전화, 컴퓨터 등 다른 디지털 자산과 함께 자가 주사 기기를 사용하기 위해 점차적으로 협력할 것으로 보입니다. 궁극적으로 환자가 자신의 치료를 훨씬 더 잘 통제할 수 있게 될 것으로 보입니다.

자가주사기 시장 보고서 하이라이트

• 시장은 제품별로 자동 주사기, 펜형 주사기, 웨어러블 주사기, 무침 주사기 등으로 분류됩니다. 무침 주사기 분야는 높은 효과와 세계 보급률로 인해 2024년 시장의 약 28.32%를 차지하며 가장 큰 점유율을 차지할 것으로 예상됩니다.
• 사용성에 따라 시장은 재사용과 일회용 부문으로 나뉩니다. 일회용 부문은 2024년 약 62.64%의 시장 점유율을 차지할 것입니다.
• 용도별로 시장은 암, 통증 관리, 자가면역질환, 호르몬 질환, 기타로 분류됩니다. 암은 주요 부문 중 하나로 2021년 시장 점유율은 약 26.82%였습니다.
• 북미 자가주사기 시장은 2024년 매출 점유율 42.44%를 차지하며 전체 세계 시장을 장악했습니다. 북미 시장은 자가 치료에 대한 환자 선호도 증가, 암 환자 증가, 호르몬 질환 증가 등 여러 요인에 의해 주도되고 있습니다.
• 아시아태평양의 자가주사기 시장은 주로 인도, 중국, 일본 등 주요 국가의 의료 인프라의 급속한 발전과 만성질환 치료에 대한 투자 증가로 인해 크게 성장하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 자가주사기 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 자가주사기 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 자가주사기 시장 : 제품 추정·동향 분석

• 부문 대시보드
• 자가주사기 시장 : 제품 변동 분석
• 자가주사기 시장 : 제품별 전망
• 2018년부터 2030년까지 시장 규모와 예측 및 동향 분석
• 오토인젝터
• 펜형 주사기
• 웨어러블 인젝터
• 무바늘 주사기

제5장 자가주사기 시장 : 사용성 추정·동향 분석

• 부문 대시보드
• 자가주사기 시장 : 사용성 변동 분석
• 사용성 전망에 의한 자가주사기 시장
• 2018년부터 2030년까지 시장 규모와 예측 및 동향 분석
• 일회용
• 재사용 가능

제6장 자가주사기 시장 : 용도 추정·동향 분석

• 부문 대시보드
• 자가주사기 시장 : 용도 변동 분석
• 자가주사기 시장 용도별 전망
• 2018년부터 2030년까지 시장 규모와 예측 및 동향 분석
• 암
• 자가면역질환
• 통증 관리
• 기타

제7장 자가주사기 시장 : 지역별 추정·동향 분석

• 지역 대시보드
• 지역별 자가주사기 시장 변동 분석
• 자가주사기 시장 : 기술과 최종 용도별 지역별 추정·동향 분석
• 2018년부터 2030년까지 시장 규모와 예측 및 동향 분석
• 북미
  • 미국
  • 캐나다
  • 멕시코
  • 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 구도

• 시장 진출 기업 분류
• 주요 기업 개요
  • YPSOMED
  • BD
  • Gerresheimer AG
  • Antares Pharma, Inc.
  • Haselmeier AG
  • NuGen Medical Devices
  • Owen Mumford Ltd.
  • SHL Medical AG.
  • Pfizer, Inc.
  • Amgen Inc.

ksm

영문 목차

영문목차

Self-injection Devices Market Growth & Trends:

The global self-injection devices market size is expected to reach USD 40.50 billion by 2030, registering a CAGR of 10.31% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing patient volume and rising prevalence of chronic diseases along with the high adoption of advanced drug delivery systems are factors estimated to surge the demand for self-injection devices.

Prevention of needlestick injury is a primary factor for healthcare professionals and companies to introduce self-injection devices such as autoinjectors. To avoid needlestick injuries to healthcare workers, the U.S., Europe, and other markets mandate the use of safety devices. Several auto-injectors provide the additional benefit of needlestick protection to healthcare professionals. It is expected that in the U.S. about 69,000 injuries can be prevented annually. Numerous auto-injectors have integral and passive safety features that eliminate or reduce the risk of injury.

Innovation in the field of New Drug Delivery Systems (NDDDS) has led to the rising demand for self-administered medications. The invention of novel injectable delivery devices such as pre-filled syringes, pen injectors, autoinjectors, and needle-free injectors has made the self-administration of drugs easier and more convenient for patients. The majority of biological drugs are delivered using injections, which include the threat of needlestick injuries. To minimize this issue, pharmaceutical firms are developing self-administered needle-free injectors and patient-friendly medication-device combination products.

The COVID-19 pandemic has altered expectations and perceptions of delivery settings and contributed to a rise in preference for self-administration medication. As this becomes the norm, several manufacturers are inclined to make the patient experience the vital component of drug delivery design. Significantly, the COVID-19 vaccines will increase the demand for injectable devices and the pandemic has also shown the benefit of self-use devices as well as connected devices. Post-pandemic there may be a rise in upcoming innovation in devices and pharma manufacturers will progressively collaborate to use self-injection devices in combination with other digital assets such as apps, phones, and personal computers. Eventually, this will bring the patient into far greater control of their care.

Self-injection Devices Market Report Highlights:

• The market is classified by product into auto-injectors, pen injectors, wearable injectors, and needle-free injectors. The needle-free injector segment held the largest share, accounting for around 28.32% of the market in 2024, due to its high effectiveness and adoption rates worldwide.
• Based on usability, the market is segmented into reusable and disposable. The disposable segment held around 62.64% market share in 2024.
• The market is segmented by application into cancer, pain management, autoimmune disorders, hormonal disorders, and others. Cancer is among the leading segments, holding around 26.82% market share in 2021.
• North America self-injection devices market dominated the overall global market and accounted for 42.44% of revenue share in 2024. The North American market is driven by several factors, including increased preference of the patients toward self-medication, increasing cancer cases, and rising cases of hormonal diseases.
• The Asia Pacific self-injection devices market is experiencing substantial growth, primarily driven by rapidly advancing healthcare infrastructure in key countries such as India, China, and Japan, alongside increasing investments in treating chronic disorders.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End-Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. End Use outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Self-injection Devices Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing preference for self-administration
    • 3.2.1.2. Rising prevalence of hormonal disorders
    • 3.2.1.3. Technological advancements
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Risk of Infection and Complications
• 3.3. Self-injection Devices Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Self-injection Devices Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Self-injection Devices Market: Product Movement Analysis
• 4.3. Self-injection Devices Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Autoinjectors
  • 4.5.1. Autoinjectors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Pen injectors
  • 4.6.1. Pen injectors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Wearable injectors
  • 4.7.1. Wearable injectors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Needle-free injectors
  • 4.8.1. Needle-free injectors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Self-injection Devices Market: Usability Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Self-injection Devices Market: Usability Movement Analysis
• 5.3. Self-injection Devices Market by Usability Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Disposable
  • 5.5.1. Disposable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Reusable
  • 5.6.1. Reusable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Self-injection Devices Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Self-injection Devices Market: Application Movement Analysis
• 6.3. Self-injection Devices Market by Application Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Cancer
  • 6.5.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Autoimmune disorders
  • 6.6.1. Autoimmune disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Pain management
  • 6.7.1. Pain management Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Others
  • 6.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Self-injection Devices Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Regional Self-injection Devices Market Movement Analysis
• 7.3. Self-injection Devices Market: Regional Estimates & Trend Analysis by Technology & End-use
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. North America
  • 7.5.1. North America Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. U.S.
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. U.S. Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. Canada Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. Mexico Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Europe
  • 7.5.6. Europe Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. UK
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement scenario
    • 7.5.7.5. UK Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Germany
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement scenario
    • 7.5.8.5. Germany Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. France
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement scenario
    • 7.5.9.5. France Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.10. Italy
    • 7.5.10.1. Key Country Dynamics
    • 7.5.10.2. Competitive Scenario
    • 7.5.10.3. Regulatory Framework
    • 7.5.10.4. Reimbursement scenario
    • 7.5.10.5. Italy Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.11. Spain
    • 7.5.11.1. Key Country Dynamics
    • 7.5.11.2. Competitive Scenario
    • 7.5.11.3. Regulatory Framework
    • 7.5.11.4. Reimbursement scenario
    • 7.5.11.5. Spain Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.12. Denmark
    • 7.5.12.1. Key Country Dynamics
    • 7.5.12.2. Competitive Scenario
    • 7.5.12.3. Regulatory Framework
    • 7.5.12.4. Reimbursement scenario
    • 7.5.12.5. Denmark Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.13. Sweden
    • 7.5.13.1. Key Country Dynamics
    • 7.5.13.2. Competitive Scenario
    • 7.5.13.3. Regulatory Framework
    • 7.5.13.4. Reimbursement scenario
    • 7.5.13.5. Sweden Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.14. Norway
    • 7.5.14.1. Key Country Dynamics
    • 7.5.14.2. Competitive Scenario
    • 7.5.14.3. Regulatory Framework
    • 7.5.14.4. Reimbursement scenario
    • 7.5.14.5. Norway Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. Japan Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. China Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement scenario
    • 7.6.4.5. India Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement scenario
    • 7.6.5.5. South Korea Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. Australia
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement scenario
    • 7.6.6.5. Australia Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement scenario
    • 7.6.7.5. Thailand Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. Brazil Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. Argentina Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Middle East & Africa
  • 7.8.1. Middle East & Africa Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement scenario
    • 7.8.2.5. South Africa Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement scenario
    • 7.8.3.5. Saudi Arabia Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement scenario
    • 7.8.4.5. UAE Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement scenario
    • 7.8.5.5. Kuwait Self-injection Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Key Company Profiles
  • 8.2.1. YPSOMED
    • 8.2.1.1. Company overview
    • 8.2.1.2. Financial performance
    • 8.2.1.3. Product benchmarking
    • 8.2.1.4. Strategic initiatives
  • 8.2.2. BD
    • 8.2.2.1. Company overview
    • 8.2.2.2. Financial performance
    • 8.2.2.3. Product benchmarking
    • 8.2.2.4. Strategic initiatives
  • 8.2.3. Gerresheimer AG
    • 8.2.3.1. Company overview
    • 8.2.3.2. Financial performance
    • 8.2.3.3. Product benchmarking
    • 8.2.3.4. Strategic initiatives
  • 8.2.4. Antares Pharma, Inc.
    • 8.2.4.1. Company overview
    • 8.2.4.2. Financial performance
    • 8.2.4.3. Product benchmarking
    • 8.2.4.4. Strategic initiatives
  • 8.2.5. Haselmeier AG
    • 8.2.5.1. Company overview
    • 8.2.5.2. Financial performance
    • 8.2.5.3. Product benchmarking
    • 8.2.5.4. Strategic initiatives
  • 8.2.6. NuGen Medical Devices
    • 8.2.6.1. Company overview
    • 8.2.6.2. Financial performance
    • 8.2.6.3. Product benchmarking
    • 8.2.6.4. Strategic initiatives
  • 8.2.7. Owen Mumford Ltd.
    • 8.2.7.1. Company overview
    • 8.2.7.2. Financial performance
    • 8.2.7.3. Product benchmarking
    • 8.2.7.4. Strategic initiatives
  • 8.2.8. SHL Medical AG.
    • 8.2.8.1. Company overview
    • 8.2.8.2. Financial performance
    • 8.2.8.3. Product benchmarking
    • 8.2.8.4. Strategic initiatives
  • 8.2.9. Pfizer, Inc.
    • 8.2.9.1. Company overview
    • 8.2.9.2. Financial performance
    • 8.2.9.3. Product benchmarking
    • 8.2.9.4. Strategic initiatives
  • 8.2.10. Amgen Inc.
    • 8.2.10.1. Company overview
    • 8.2.10.2. Financial performance
    • 8.2.10.3. Product benchmarking
    • 8.2.10.4. Strategic initiatives

관련자료